(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of -40.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Meiragtx Holdings's revenue in 2026 is $397,501,000.On average, 9 Wall Street analysts forecast MGTX's revenue for 2026 to be $33,025,344,605, with the lowest MGTX revenue forecast at $30,563,762,617, and the highest MGTX revenue forecast at $35,973,864,582. On average, 8 Wall Street analysts forecast MGTX's revenue for 2027 to be $7,670,858,048, with the lowest MGTX revenue forecast at $3,764,885,443, and the highest MGTX revenue forecast at $16,932,380,195.
In 2028, MGTX is forecast to generate $15,234,340,026 in revenue, with the lowest revenue forecast at $4,706,490,976 and the highest revenue forecast at $30,297,723,518.